Additionally, NKG2D-CAR-induced NK cells incorporating a costimulatory domain exhibited significant and robust anti-tumor activity, leading to enhanced tumor clearance and prolonged survival in preclinical models of tumors expressing NKG2D ligands, including ovarian cancer, glioblastoma, and multiple myeloma (50). Here, KLRK1 is linked to ovarian cancer.